MorphoSys AG | Balance Sheet

Fiscal year is January-December. All values EUR Thousands.
2013
2014
2015
2016
2017
2018
Cash & Short Term Investments
271,336.00
145,766.00
188,341.00
144,223.00
163,527.30
358,963.80
Total Accounts Receivable
129,806.00
174,873.00
108,180.00
149,882.00
161,032.80
20,741.40
Inventories
731.00
556.00
369.00
310.00
300.80
245.20
Other Current Assets
4,694.00
1,200.00
3,226.00
13,641.00
15,819.80
8,954.90
Total Current Assets
406,567.00
322,395.00
300,116.00
308,056.00
340,680.60
388,905.30
Net Property, Plant & Equipment
2,168.00
3,558.00
3,474.00
4,189.00
3,526.40
3,530.70
Total Investments and Advances
1,727.00
2,327.00
800.00
900.00
700.00
95,981.10
Long-Term Note Receivable
-
50,030.00
15,511.00
79,521.00
-
-
Intangible Assets
35,149.00
45,979.00
79,647.00
67,939.00
67,846.90
47,365
Other Assets
1,732.00
452.00
149.00
2,995.00
2,644.30
2,981.70
Total Assets
449,805.00
428,351.00
400,079.00
463,600.00
415,398.20
538,763.80
Accounts Payable
1,078.00
569.00
237.00
8,457.00
4,622.00
Income Tax Payable
2,690.00
777.00
1,698.00
1,652.00
314.90
Other Current Liabilities
31,639.00
31,357.00
25,535.00
28,193.00
42,764.10
Total Current Liabilities
35,407.00
32,703.00
27,470.00
38,302.00
47,701.00
Long-Term Debt
299.00
252.00
225.00
218.00
87.80
Provision for Risks & Charges
637.00
43.00
43.00
23.00
23.20
Deferred Taxes
313.00
1,737.00
6,710.00
7,422.00
7,811.30
Other Liabilities
59,168.00
44,677.00
2,513.00
2,175.00
1,103.90
Total Liabilities
97,660.00
79,548.00
37,343.00
48,140.00
56,727.20
Common Equity (Total)
352,145.00
348,803.00
362,736.00
415,460.00
358,671.00
Total Shareholders' Equity
352,145.00
348,803.00
362,736.00
415,460.00
358,671.00
Total Equity
352,145.00
348,803.00
362,736.00
415,460.00
358,671.00
Liabilities & Shareholders' Equity
449,805.00
428,351.00
400,079.00
463,600.00
415,398.20

About MorphoSys

View Profile
Address
SemmelweisstraƟe 7
Planegg Bayern (Bavaria) 82152
Germany
Employees -
Website http://www.morphosys.de
Updated 07/08/2019
MorphoSys AG engages in the development of antibodies for therapeutic, diagnostics, and research applications. It operates through the Proprietary Development and Partnered Discovery segments. The Proprietary Development segment combines proprietary research and development of therapeutic compounds.